ANDOVER, Mass.--(BUSINESS WIRE)--DeuteRx, LLC, is a research and development-focused biotechnology company dedicated to improving racemic small molecule marketed drugs and drug candidates intended for ...
Making carbon–carbon bonds is hard. Linking racemic mixtures of two alkyls while simultaneously controlling the stereochemistry of both ends of the product is nigh on impossible. Now Gregory Fu, ...
A racemic mixture of tartaric acid forms mirror-image domains with equal propensity when adsorbed on a copper surface. When one enantiomer is present in a slight excess, however, only ordered domains ...
THE separation of racemic mixtures of optical isomers is still limited, with rare exceptions, to the methods of Pasteur. For this reason the resolution of substances which seem identical in the ...
When chemists need to separate one chiral molecule from a mixture of enantiomers—for instance, when synthesizing potential drug molecules—they often turn to high-performance liquid chromatography ...
From 2001 to 2011, the US Food and Drug Administration approved 9 single-enantiomer drugs with racemic precursors. None showed pre-approval evidence of improved efficacy over the racemic precursor. We ...
In Sumitomo Dainippon Pharma Co. V. Emcure Pharm. Ltd., the Federal Circuit affirmed the district court’s decision that construed a chemical structure as reading on the lurasidone enantiomer that is ...
New biocatalytic and chemocatalytic routes to chiral intermediates and developments in simulated-moving-bed and supercritical-fluid chromatography for resolving racemic mixtures. The prevalence of ...
A quote from Rudolph Buchheim, an experimental pharmacologist who lived from 1820 to 1879, summarizes the nature and importance of studies in drug metabolism, including the pharmacokinetics and ...
On April 16, 2018 in a precedential opinion, the United States Court of Appeals for the Federal Circuit, Sumitomo Dainippon Pharma v. Emcure Pharms., Nos. 2017-1798, -1799, -1800, affirmed the United ...
As a general rule, disclosure of a drug material comprised of a mixture of components, without more, does not render obvious a specific component of that mixture. See, e.g., In re May, 574 F.2d 1082, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback